Intervacc's Chief Scientific Officer Dr Andrew Waller presents at the FEEVA European Horse Welfare Symposium in Amsterdam
Stockholm, January 24, 2023 - Intervacc's Chief Scientific Officer Dr Andrew Waller will talk about the prevention of equine strangles at the Federation of European Equine Veterinary Associations (FEEVA) European Horse Welfare Symposium 2023 on the 28th of January. The symposium is taking place in connection with Jumping Amsterdam.
"It's a fantastic opportunity to speak about equine strangles directly to the core members and the extended network of FEEVA, who are all equine veterinarians from Europe with a passion for horse welfare. I'm really excited to be able to discuss the new tools that can prevent this terrible disease and reduce the suffering it causes to horse populations in the EU and throughout the world", says Dr Andrew Waller, Chief Scientific Officer at Intervacc. "2022 was a tough year for strangles cases and we've already seen several fatal cases of strangles in 2023. I'm really looking forward to working with vets throughout Europe to begin reversing this trend."
FEEVA is the umbrella equine veterinary association in Europe, founded 1998 and now representing 20 member countries and more than 7000 equine veterinarians. Today FEEVA has established working groups on Medicines, Horse Welfare, Disease Surveillance and Pre-Purchase Examination and has a mission to be the leading voice of European equine veterinarians guarding both the equine veterinary profession and horse welfare.
Dr Andrew Waller studied the evolution, transmission, and prevention of Streptococcus equi and Streptococcus zooepidemicus for over 17 years in his role as Head of Bacteriology at the Animal Health Trust. He collaborates with world leading researchers in over 20 countries around the world, has published over 80 peer-reviewed papers on streptococcal infections of animals and has utilised these research findings to develop novel diagnostic tests and vaccines with which to improve animal health. Andrew joined Intervacc in 2020 where he continues to work towards improving the health of animals.
Strangles, caused by Streptococcus equi, remains one of the most prevalent infectious diseases of horses worldwide. The transmission of S. equi is facilitated by its ability to persist within the guttural pouches of recovered horses, presenting a challenge to the diagnosis, treatment, and prevention of infection. Andrew's presentation will describe how this host-restricted pathogen establishes infection and evades host immune responses to be transmitted to naïve animals. The diagnosis, treatment, and prevention of strangles provide opportunities to break the cycle of infection towards the eradication of S. equi from premises with endemic infection. Andrew will describe the latest advances in diagnostic and preventative measures towards improving the health of horses.
For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: [email protected]
The information was submitted for publication, through the agency of the contact person set out above on January 24, 2023, 13.00 CET.
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: [email protected],Phone: +46 (0)8 - 684 211 10